<DOC>
	<DOCNO>NCT02049476</DOCNO>
	<brief_summary>The main purpose study evaluate whether dexamethasone pellet ( Ozurdex® , Allergan , Irvine , CA ) replace oral corticosteroid ( e.g . prednisone ) treatment active sight-threatening , noninfectious intermediate and/or posterior uveitis immunosuppressive drug therapy indicate . Uveitis inflammation inside eye . Uveitis decrease patient ' vision treat . The dexamethasone pellet implant fill corticosteroid medicine . This therapy approve Food Drug Administration ( FDA ) treatment intermediate and/or posterior uveitis . In study investigator want see use implant together systemic immunosuppressive drug therapy result low ocular side effect profile effective enough replace use high-dose systemic corticosteroid treatment active intermediate and/or posterior uveitis . Knowing effectiveness safety treatment important kind uveitis study usually need treat many year . This information may help researcher understand uveitis good may suggest way improve treatment . Adult patient intermediate and/or posterior uveitis immunosuppressive drug therapy high-dose corticosteroid plan may join .</brief_summary>
	<brief_title>Study Effectiveness Ozurdex Control Uveitis</brief_title>
	<detailed_description>Objectives : This single arm study evaluate whether dexamethasone pellet ( Ozurdex® , Allergan , Irvine , CA ) replace oral corticosteroid ( e.g . prednisone ) treatment active sight-threatening , noninfectious intermediate posterior uveitis immunosuppressive drug therapy indicate . Background : Intermediate posterior uveitis thought severe intraocular inflammation may lead permanent visual loss . It estimate form uveitis comprise fifth sixth lead cause blindness tend affect work class age patient , thus cause loss work hour diminish productivity quality life . Because posterior segment eye adequately treat corticosteroid drop often systemic drug therapy use include oral corticosteroid prednisone . Prednisone myriad side effect approximately one-quarter one-third case treat tertiary care center , additional medication immunosuppressive drug require control disease and/or allow appropriate taper oral prednisone subsequent level low side effect profile deliver long period time . Typically , chronic prednisone therapy dose 7.5 mg daily less thought low enough side effect profile amenable long-term therapy . However frequently immunosuppressive drug require get dosing level . There occasion patient intolerant dose oral corticosteroid intolerant high dose oral corticosteroid ( 30 - 60 mg daily ) therefore treatment modality avoid due prednisone 's attendant side effect . Although periocular intravitreal corticosteroid injection may perform , modality standard care wait disease reactivate institute therapy therefore chronic suppressive dose obtain . The fluocinolone acetonide implant ( Retisert® , Bausch Lomb , Tampa , FL ) FDA-approved treatment intermediate posterior uveitis equally effective control uveitis high-dose oral corticosteroid avoids systemic side effect associate use high dos oral corticosteroid . However , form local therapy high rate ocular side effect , include ocular hypertension cause glaucoma and/or require glaucoma surgery cataract . Furthermore , every two half three year implant exhaust corticosteroid therefore repeat surgical insertion another implant may require . A useful potential therapy treatment patient would shorter-acting local corticosteroid could deliver conjunction systemic immunosuppressive drug therapy would lower ocular side effect profile still would effective enough replace use high-dose systemic corticosteroid treatment active intermediate posterior uveitis . It possible dexamethasone pellet could fill unique role treatment uveitis . Investigators propose study evaluate dexamethasone pellet specific use among patient active intermediate posterior uveitis .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Uveitis , Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Active sightthreatening intermediate posterior uveitis immunosuppressive drug therapy plan physician consider treatment highdose corticosteroid control uveitis whilst immunosuppressive drug institute adjust . Note : acceptable patient already immunosuppressive drug long high dose corticosteroid indicate . Patients must age 18 year old ( dexamethasone pellet FDAapproved pediatric use ) sign inform consent . The ocular medium must clear enough obtain optical coherence photography ( OCT ) fundus photograph . No elective intraocular surgery plan first 3 month enrollment . Infectious uveitis History scleritis Active suspect viral infection cornea conjunctiva History mycobacterial fungal disease HIV positivity Age &lt; 18 year old Allergy dexamethasone Uncontrolled IOP Advanced glaucoma Aphakia rupture posterior lens capsule Anterior chamber IntraOcualr Lens ( ACIOL ) rupture posterior lens capsule Media opacity would preclude evaluation posterior pole via fundus photography OCT assessment Planned elective ocular surgery within 3 month enrollment Any systemic disease require systemic corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Uveitis , Intermediate</keyword>
	<keyword>Uveitis , Posterior</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Eye Abnormalities</keyword>
	<keyword>Eye Diseases</keyword>
	<keyword>Ophthalmology</keyword>
	<keyword>Ophthalmologic Surgical Procedures</keyword>
	<keyword>Vision Disorders</keyword>
	<keyword>Inflammation</keyword>
</DOC>